Sign in

    Luke Lapointe

    Director specializing in Medical Technology within the Global Healthcare Group at Robert W. Baird & Co.

    Luke Lapointe is a Director specializing in Medical Technology within the Global Healthcare Group at Robert W. Baird & Co., leveraging extensive expertise in M&A transactions for healthcare and medtech clients. Since joining Baird in 2014 from a boutique healthcare investment bank, he has advised on numerous high-profile deals involving innovative medical technology companies, contributing to the firm's reputation for executing efficient and competitive processes with strong outcomes for private equity and strategic buyers. Lapointe earned a bachelor’s degree in management with a concentration in finance from Boston College and is affiliated with a FINRA-member firm, indicating securities licensure. His professional track record demonstrates senior leadership and key industry insights in the evolving medical technology space.

    Luke Lapointe's questions to REGENXBIO (RGNX) leadership

    Luke Lapointe's questions to REGENXBIO (RGNX) leadership • Q1 2025

    Question

    Speaking for Brian Skorney, Luke Lapointe of Baird asked if the company has set a target for the quantity of RGX-202 commercial product it expects to have available at launch.

    Answer

    President and CEO Curran Simpson explained that while a specific number is still under evaluation, the goal is to have a significant number of doses ready to quickly address the prevalent ambulatory market, which they estimate at 5,000-7,000 patients. He reiterated their facility can produce 2,500 doses annually, enabling them to build a substantial inventory before launch.

    Ask Fintool Equity Research AI